Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 11/20 | 0.63 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133927 | 0.92 | ADA (0.75) | ADAPPARGPPARA | |
| SCHEMBL5672327 | 0.86 | ADA (0.64) | ADA | |
| SCHEMBL5670994 | 0.86 | ADA (0.80) | ADAPPARGPPARAALOX5ALDH1A1 | |
| SCHEMBL5672375 | 0.85 | ADA (0.59) | ADA | |
| SCHEMBL5671214 | 0.83 | ADA (0.56) | ADACYP3A4 | |
| SCHEMBL5673392 | 0.81 | ADA (0.55) | ADA | |
| SCHEMBL5672345 | 0.81 | ADA (0.57) | ADA | |
| SCHEMBL5671892 | 0.81 | ADA (0.55) | ADA | |
| SCHEMBL6134005 | 0.80 | ADA (0.54) | ADAMCL1 | |
| SCHEMBL6171224 | 0.80 | ADA (0.57) | ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064144-B2 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2006-06-20 | — | — | US | claimed |
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-11-25 | — | — | US | claimed |
| US-7064144-B2 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ADA, ADAR, IMPDH1 | ADA 1/4885PPARG 2894/4885PPARA 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.